FDA Lifts Holds on 2 Nivolumab Myeloma Trials
December 6, 2017 - The FDA has lifted partial clinical holds placed on the phase I CheckMate-039 and phase II CA204142 trials exploring nivolumab-based regimens in patients with relapsed/refractory multiple myeloma. The agency placed the partial holds on the studies in October, ...Leggi tutto